Overview

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2031-05-01
Target enrollment:
Participant gender:
Summary
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Active Biotech AB
Treatments:
ruxolitinib
tasquinimod